The Zacks Analyst Blog Highlights: Merck, GlaxoSmithKline, VIVUS, Santarus and Celgene

The Zacks Analyst Blog Highlights: Merck, GlaxoSmithKline, VIVUS, Santarus and

PR Newswire

CHICAGO, April 30, 2013

CHICAGO, April 30, 2013 /PRNewswire/ announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Merck & Co. Inc. (NYSE:MRK),
GlaxoSmithKline (NYSE:GSK), VIVUS Inc. (Nasdaq:VVUS), Santarus, Inc.
(Nasdaq:SNTS) and Celgene Corporation (Nasdaq:CELG).


Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter:

Here are highlights from Monday's Analyst Blog:

Merck Likely to Beat Earnings

We expect Merck & Co. Inc. (NYSE:MRK) to beat earnings expectations when it
reports first-quarter 2013 results before the opening bell on May 1, 2013.
Why a Likely Positive Surprise?

Our proven model shows that Merck has the right combination of two key
ingredients to beat earnings.

Positive Zacks ESP: The earnings Expected Surprise Prediction (ESP) (Read:
Zacks Earnings ESP: A Better Method) for Merck is +1.28% – the difference
between the Most Accurate earnings estimate of 79 cents per share and the
Zacks Consensus Estimate of 78 per share. This indicates a likely positive
earnings surprise.

Zacks Rank #3 (Hold): Merck carries a Zacks Rank #3. Note that stocks with
Zacks Rank of #1, #2 and #3 have a significantly higher chance of beating
earnings. The Sell rated stocks (#4 and #5) should never be considered while
going into an earnings announcement.

The combination of its Zacks Rank and Earnings ESP for Merck makes us
confident of a positive earnings surprise in the to-be-reported quarter.

Drivers of Better-than-Expected Earnings

While headwinds remain in the form of the Singulair genericization, EU pricing
pressure, unfavorable currency movement, US health care reform and pipeline
setbacks, some of the company's recent launches should start contributing
significantly to the top line in the first quarter.

Products that should add significantly to revenues include hepatitis C virus
(HCV) drug Victrelis, fertility drug Elonva, Saphris (acute treatment of
schizophrenia and bipolar I disorder in adults), Simponi (treatment of certain
inflammatory diseases), Dulera (asthma), and Daxas (chronic obstructive
pulmonary disease) among others. Additionally we believe Merck's Januvia
(sitagliptin) for type-II diabetes should continue to benefit from regulatory
restrictions imposed on competitor GlaxoSmithKline's (NYSE:GSK) Avandia.

This company has delivered positive earnings surprises in the last four
quarters with an average beat of 2.66%. We expect the trend to continue.

Other Stocks to Consider

Merck is not the only company looking up this earnings season. Here are some
other stocks you may want to consider as our model shows these have the right
combination of elements to post an earnings beat this season:

VIVUS Inc. (Nasdaq:VVUS) has an earnings ESP of +7.84% and holds a Zacks Rank

Santarus, Inc. (Nasdaq:SNTS) has an earnings ESP of +8.33% and holds a Zacks
Rank #3.

CHMP in Favor of Celgene's Revlimid

Good news flowed in at Celgene Corporation (Nasdaq:CELG) from Europe when the
Committee for Human Medicinal Products (CHMP) of the European Medicines Agency
(EMA) recommended the approval of its cancer drug Revlimid in the EU for the
myelodysplastic syndrome (MDS) indication. The positive opinion by the CHMP
will be reviewed by the European Commission, which should issue a final
decision in two to three months.

Celgene is seeking EU approval for the use of Revlimid for treating patients
with transfusion-dependent anemia due to low or intermediate-1-risk MDS
associated with an isolated deletion 5q cytogenetic abnormality. The patients
did not respond adequately to other therapies for the disease.

The CHMP issued the positive opinion on the basis of encouraging data from the
phase III MDS-004 study (n=205). The study, conducted across multiple European
centers, evaluated the efficacy and safety of Revlimid versus placebo.

We note that Revlimid, the principal growth driver at Celgene, is already
approved for the MDS indication in many countries including the US, Canada,
Switzerland, Australia, New Zealand, Malaysia, and Israel apart from several
Latin American nations. The drug is also approved in many countries across the
globe in combination with dexamethasone for treating multiple myeloma patients
who have received at least one prior therapy. Approval in the EU for the MDS
indication would further boost the sales potential of Revlimid.

Apart from Revlimid, the oncology portfolio at Celgene includes drugs such as
Vidaza, Abraxane, Pomalyst and Thalomid. Celgene also boasts of an interesting
and diversified pipeline. A number of pipeline-related news is expected in the
coming quarters. We believe that the successful development and
commercialization of the pipeline would boost Celgene's top line further.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at

Visit for information about the performance
numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.